Avaxia Biologics

Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.

Avaxia Biologics (www.avaxiabiologics.com) is a private, early stage company developing orally-delivered antibody therapeutics using a proprietary antibody platform. The company is pursuing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity. Avaxia's lead product is a proprietary anti-TNF antibody to be administered to the oral cavity of patients suffering from mucositis. The antibody is designed to reduce the pain and ulceration associated with this serious side effect of cancer treatment. Avaxia is also developing a proprietary anti-TNF antibody to be administered orally to patients suffering from inflammatory bowel disease. Avaxia is also conducting discovery programs in the field of diabetes and obesity, targeting critical intestinal receptors associated with glucose metabolism.